L-ARGININE THERAPY FOR PLACENTAL INSUFFICIENCY AND IMPAIRED FETAL PERFUSION :A PRECISION MEDICINE APPROACH INTEGRATING NITRIC OXIDE BIOMARKERS, MICROBIOME AND NUTRIGENOMICS DETERMINANTS

Abstract
Normal pregnancy requires adequate uteroplacental blood flow, which is largely regulated by
nitric oxide (NO) produced from L-arginine via nitric oxide synthase. Nitric oxide plays an
essential role in vasodilation, regulation of vascular tone, maintenance of endothelial
function, inhibition of platelet aggregation, and improvement of uteroplacental circulation,
thereby ensuring sufficient oxygen and nutrient supply to the developing fetus. In certain
pregnancy complications such as placental insufficiency, intrauterine growth restriction, and
early endothelial dysfunction, nitric oxide bioavailability may decline, leading to impaired
vascular relaxation and reduced fetal perfusion. Emerging evidence suggests that factors
including maternal microbiome composition, nutrigenomic variations in arginine metabolism,
hormonal changes, and metabolic stress may further influence nitric oxide synthesis during
pregnancy. However, conventional nutritional supplementation strategies rarely consider
these underlying determinants. This study proposes a personalized approach to L-arginine
nutritional supplementation by identifying pregnancy-related factors that contribute to nitric
oxide depletion and evaluating how targeted nutritional supplementation may improve
maternal vascular function and fetal outcomes. Pregnant women presenting with risk
indicators of impaired placental circulation will be evaluated for nitric oxide–related
biomarkers, metabolic parameters, and nutritional status. Selected participants will receive
oral L-arginine nutritional supplementation aimed at restoring nitric oxide production.
Additional factors such as maternal microbiome balance, nutrigenomic influences on arginine
metabolism, and hormonal profiles will be analyzed to determine their relationship with nitric
oxide bioavailability. Maternal hemodynamic parameters and fetal growth indicators will be
monitored to assess supplementation response. This approach highlights the potential of
precision medicine in obstetric pharmacotherapy, where understanding individual biological
factors influencing nitric oxide metabolism could optimize L-arginine therapy and improve
maternal-fetal outcomes.
Keywords: L-arginine; Nitric oxide; Uteroplacental blood flow; Nutrigenomics; Maternal
microbiome